<DOC>
	<DOCNO>NCT00704652</DOCNO>
	<brief_summary>The purpose study determine whether systemic administration darbepoetin alpha result progression regression diabetic macular edema .</brief_summary>
	<brief_title>Evaluation Retinal Changes Systemic Darbepoetin Alpha Treatment Patients With Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Group A : Males female age 18 80 yr Diabetes mellitus type 1 2 Haemoglobin level treatment threshold level ( describe drug description ) Receiving darbepoetin alfa treatment Best Corrected Visual Acuity ( BCVA ) good 20/200 No clinically significant macular edema ( CSME ) CSME already treat laser photocoagulation . Group B : Males female age 18 80 yr Diabetes mellitus type 1 or2 Anaemia ( due renal failure ) , haemoglobin level treatment threshold level initialisation therapy ( describe drug label ) Starting receive darbepoetin alfa treatment ( darbepoetin alfa , Aranesp , Amgen ) BCVA better 20/200 No clinically significant macular edema ( CSME ) CSME already treat laser photocoagulation . History retinal disease DR History intraocular surgery , include laser treatment past 4 month A major change insulin treatment patient past 4 month follow period . Inability communicate German English Dementia ; inability follow command Epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>